Mark Pruzanski
2017
In 2017, Mark Pruzanski earned a total compensation of $6.2M as President and Chief Executive Officer at Intercept Pharmaceuticals, a 29% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $401,625 |
|---|---|
| Option Awards | $2,583,556 |
| Salary | $675,000 |
| Stock Awards | $2,486,576 |
| Other | $7,930 |
| Total | $6,154,687 |
Pruzanski received $2.6M in option awards, accounting for 42% of the total pay in 2017.
Pruzanski also received $401.6K in non-equity incentive plan, $675K in salary, $2.5M in stock awards and $7.9K in other compensation.
Rankings
In 2017, Mark Pruzanski's compensation ranked 1,420th out of 14,666 executives tracked by ExecPay. In other words, Pruzanski earned more than 90.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,420 out of 14,666 | 90th |
Division Manufacturing | 485 out of 5,772 | 92nd |
Major group Chemicals And Allied Products | 126 out of 2,075 | 94th |
Industry group Drugs | 89 out of 1,731 | 95th |
Industry Pharmaceutical Preparations | 70 out of 1,333 | 95th |
Source: SEC filing on April 27, 2018.
Pruzanski's colleagues
We found four more compensation records of executives who worked with Mark Pruzanski at Intercept Pharmaceuticals in 2017.